EUVIMEDEUVIMED entdecken
Übersichtsarbeit

▼Naltrexone/bupropion for obesity

Drug and Therapeutics Bulletin · 2017-11 · 55 (11) · 126-129

DOI: 10.1136/dtb.2017.11.0550 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug and Therapeutics Bulletin, online erschienen am 08.11.2017. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

▼ Naltrexone/bupropion (Mysimba - Orexigen Therapeutics Ireland Limited) is a fixed-dose combination product for the treatment of adults who are obese or overweight with at least one weight-related comorbidity, as an adjunct to diet and lifestyle modifications. Originally licensed by the European Medicines Agency (EMA) in 2015, it has recently been launched in the UK. Here, we review the evidence for its efficacy and safety and consider its place in therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsBupropionChemotherapy, AdjuvantDrug CombinationsHumansNaltrexoneObesity, MorbidRandomized Controlled Trials as Topic

Substanzen

Anti-Obesity AgentsDrug Combinationsbupropion hydrochloride, naltrexone hydrochoride drug combinationBupropionNaltrexone

Zitieren

APA

(2017). ▼Naltrexone/bupropion for obesity. Drug and Therapeutics Bulletin, 55(11), 126-129. https://doi.org/10.1136/dtb.2017.11.0550

Vancouver

▼Naltrexone/bupropion for obesity. Drug and Therapeutics Bulletin. 2017;55(11):126-129. doi:10.1136/dtb.2017.11.0550

BibTeX
@article{euvimed2017,
  title = {▼Naltrexone/bupropion for obesity},
  journal = {Drug and Therapeutics Bulletin},
  year = {2017},
  volume = {55},
  number = {11},
  pages = {126--129},
  doi = {10.1136/dtb.2017.11.0550}
}
Kostenlos starten →